Forecast for Humacyte Inc. stock (ticker symbol: HUMA) in 2025 varies significantly depending on the source analyzed, reflecting the uncertainties surrounding this biotechnology company.

🔍 Optimistic estimates (Wall Street analyses)

Wall Street analysts provide a positive outlook on HUMA, with an average target price of $11.20 and estimates ranging between $4.00 and $25.00. This indicates a growth potential of over 360% compared to the current price of approximately $2.53. Most analysts recommend "Buy," and some even "Strong Buy".

⚠️ Cautious estimates (algorithmic models)

On the other hand, algorithm-based platforms, such as CoinCodex and StockScan, offer more conservative forecasts. They estimate an average price for 2025 between $1.65 and $2.53, suggesting stagnation or even a slight decrease from the current level. The overall technical sentiment is predominantly negative, with 69% of indicators signaling a downward trend.

📊 Summary of forecasts for 2025

Source Average target price Estimated range Recommendation

Wall Street $11.20 $4.00 – $25.00 Buy / Strong Buy

CoinCodex $2.00 $1.70 – $2.53 Sell (bearish trend)

StockScan $1.65 $0.0136 – $3.29 Sell

🧠 Conclusion

HUMA is a stock with a high-risk profile but significant potential, especially if its biotechnology products achieve commercial success. Interested investors should closely monitor the company's clinical and financial developments and consider portfolio diversification to manage risk.